Syncom Formulations, a Small Cap company in the Drug Manufacturers - Specialty & Generic Industry has delivered 2782.8% returns in 5-year showing 13.5% quarterly revenue growth with 10.6% profit margin, making it a potential Multibagger.
To predict the Syncom Formulations's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Syncom Formulations Share Price Target For 2025
The line chart displays the monthly closing prices of Syncom Formulations with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Syncom Formulations shares in 2025, see the table below.
Syncom Formulations Share Price Target Table For 2025
Short-Term Technical Outlook
Current Technical Position: Syncom Formulations is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹18.16 serves as the nearest technical reference point.
Historical Returns: 3-month: -8.25% | 6-month: -10.57% | 1-year: +26.37%
Syncom Formulations Share Price Target For 2026
The line chart displays the monthly closing prices of Syncom Formulations with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Syncom Formulations shares in 2026, see the table below.
Syncom Formulations Share Price Target Table For 2026
Long-Term Technical Outlook
52-Week Range Analysis: Syncom Formulations is currently trading at 41.7% of its 52-week range (₹10.95 - ₹27.9).
Long-Term Trend Analysis: The stock shows mixed long-term signals, trading near key moving averages.
Long-Term Performance: 1-year: +26.37% | 3-year: +94.21% | 5-year: +2,782.81%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Syncom Formulations Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Syncom Formulations Brief Company Overview
Syncom Formulations (India) Limited: A Trusted Pharmaceutical Manufacturer Syncom Formulations (India) Limited, established in 1988, is a leading pharmaceutical manufacturer headquartered in Indore, India. The company boasts a diverse product portfolio that includes...
Syncom Formulations Financial Performance
Is Syncom Formulations A Good Buy For Long Term?
Syncom Formulations, a small-cap stock with a market cap of 1,224.82 Crore, has shown promising growth in the last 12 months, generating a revenue of 249.79 Crore and a net profit of 26.38 Crore. Its strong revenue and earnings growth, along with healthy margins, indicate potential for long-term growth. Despite a current debt of 80.08 Crore, the company's cash balance of 61.38 Crore provides financial stability. Investors looking for a long-term investment opportunity in the pharmaceuticals sector may consider Syncom Formulations.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
No comments:
Post a Comment